Anavex Life Sciences Corp
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $9.21
- Today's High:
- $9.55
- Open Price:
- $9.4
- 52W Low:
- $7.13
- 52W High:
- $15.24
- Prev. Close:
- $9.54
- Volume:
- 1908500
Company Statistics
- Market Cap.:
- $744.43 million
- Book Value:
- 1.732
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -21.05%
- Return on Equity TTM:
- -35.57%
Company Profile
Anavex Life Sciences Corp had its IPO on 2006-08-02 under the ticker symbol AVXL.
The company operates in the Healthcare sector and Biotechnology industry. Anavex Life Sciences Corp has a staff strength of 38 employees.
Stock update
Shares of Anavex Life Sciences Corp opened at $9.4 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $9.21 - $9.55, and closed at $9.51.
This is a -0.31% slip from the previous day's closing price.
A total volume of 1,908,500 shares were traded at the close of the day’s session.
In the last one week, shares of Anavex Life Sciences Corp have slipped by -1.76%.
Anavex Life Sciences Corp's Key Ratios
Anavex Life Sciences Corp has a market cap of $744.43 million, indicating a price to book ratio of 4.8312 and a price to sales ratio of 0.
In the last 12-months Anavex Life Sciences Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Anavex Life Sciences Corp's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Anavex Life Sciences Corp’s operating margin was 0% while its return on assets stood at -21.05% with a return of equity of -35.57%.
In Q4, Anavex Life Sciences Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Anavex Life Sciences Corp’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.66 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Anavex Life Sciences Corp’s profitability.
Anavex Life Sciences Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -10.5764. Its price to sales ratio in the trailing 12-months stood at 0.
Anavex Life Sciences Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $148.37 million
- Total Liabilities
- $6.21 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Anavex Life Sciences Corp ended 2023 with $148.37 million in total assets and $0 in total liabilities. Its intangible assets were valued at $148.37 million while shareholder equity stood at $135.12 million.
Anavex Life Sciences Corp ended 2023 with $0 in deferred long-term liabilities, $6.21 million in other current liabilities, 78033.00 in common stock, $-258535501.00 in retained earnings and $0 in goodwill. Its cash balance stood at $143.62 million and cash and short-term investments were $143.62 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Anavex Life Sciences Corp’s total current assets stands at $143.62 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $4.09 million compared to accounts payable of $5.29 million and inventory worth $0.
In 2023, Anavex Life Sciences Corp's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Anavex Life Sciences Corp paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $9.51
- 52-Week High
- $15.24
- 52-Week Low
- $7.13
- Analyst Target Price
- $43
Anavex Life Sciences Corp stock is currently trading at $9.51 per share. It touched a 52-week high of $15.24 and a 52-week low of $15.24. Analysts tracking the stock have a 12-month average target price of $43.
Its 50-day moving average was $10.25 and 200-day moving average was $10.34 The short ratio stood at 14.94 indicating a short percent outstanding of 0%.
Around 304.3% of the company’s stock are held by insiders while 3520.3% are held by institutions.
Frequently Asked Questions About Anavex Life Sciences Corp
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson’s disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company’s drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson’s, and Alzheimer’s diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.